WO2008078725A1 - チアゼピン誘導体 - Google Patents

チアゼピン誘導体 Download PDF

Info

Publication number
WO2008078725A1
WO2008078725A1 PCT/JP2007/074780 JP2007074780W WO2008078725A1 WO 2008078725 A1 WO2008078725 A1 WO 2008078725A1 JP 2007074780 W JP2007074780 W JP 2007074780W WO 2008078725 A1 WO2008078725 A1 WO 2008078725A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
substituent group
independently selected
substituents independently
halogeno
Prior art date
Application number
PCT/JP2007/074780
Other languages
English (en)
French (fr)
Inventor
Toru Hasegawa
Tsuyoshi Shinozuka
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Priority to JP2008551103A priority Critical patent/JPWO2008078725A1/ja
Priority to EP07860009A priority patent/EP2119719A1/en
Publication of WO2008078725A1 publication Critical patent/WO2008078725A1/ja
Priority to US12/493,056 priority patent/US20100004221A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

 本発明は、優れた11β-ヒドロキシステロイドデヒドロゲナーゼタイプ1阻害作用を有する一般式(I)で表されるチアゼピン誘導体又はその薬理上許容される塩に関する。[式中、R1は、水素原子、C1-C6アルキル基等;R2は、C1-C6アルキル基、C1-C6ハロゲン化アルキル基、C1-C6ヒドロキシアルキル基等;R3は、水素原子又はC1-C6アルキル基;R4は、置換基群aから選択される基で独立に1乃至5個置換されていてもよいC6-C10アリール基又は置換基群aから選択される基で独立に1乃至3個置換されていてもよい複素環基;置換基群aは、ハロゲン原子、C1-C6アルキル基、置換基群bから選択される基で独立に1乃至5個置換されていてもよいC6-C10アリール基等;置換基群bは、ハロゲン原子、C1-C6アルキル基、C1-C6ハロゲン化アルキル基等]
PCT/JP2007/074780 2006-12-26 2007-12-25 チアゼピン誘導体 WO2008078725A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2008551103A JPWO2008078725A1 (ja) 2006-12-26 2007-12-25 チアゼピン誘導体
EP07860009A EP2119719A1 (en) 2006-12-26 2007-12-25 Thiazepine derivative
US12/493,056 US20100004221A1 (en) 2006-12-26 2009-06-26 Thiazepine derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-348763 2006-12-26
JP2006348763 2006-12-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/493,056 Continuation US20100004221A1 (en) 2006-12-26 2009-06-26 Thiazepine derivative

Publications (1)

Publication Number Publication Date
WO2008078725A1 true WO2008078725A1 (ja) 2008-07-03

Family

ID=39562514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074780 WO2008078725A1 (ja) 2006-12-26 2007-12-25 チアゼピン誘導体

Country Status (5)

Country Link
US (1) US20100004221A1 (ja)
EP (1) EP2119719A1 (ja)
JP (1) JPWO2008078725A1 (ja)
TW (1) TW200835502A (ja)
WO (1) WO2008078725A1 (ja)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011007756A1 (ja) 2009-07-13 2011-01-20 武田薬品工業株式会社 複素環化合物及びその用途
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012144478A1 (ja) 2011-04-19 2012-10-26 第一三共株式会社 テトラヒドロチアゼピン誘導体
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2746277A1 (en) 2012-12-19 2014-06-25 Basf Se Fungicidal imidazolyl and triazolyl compounds
US8822699B2 (en) 2010-09-02 2014-09-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2796381A1 (fr) * 1999-07-12 2001-01-19 Hoechst Marion Roussel Inc Derives bicycliques de thioazepine ou de caprolactame, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
US6521666B1 (en) 1998-01-20 2003-02-18 Tanabe Seiyaku Co., Ltd. Inhibitors of α4 mediated cell adhesion
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
EP1445253A1 (en) 2001-11-16 2004-08-11 Yamanouchi Pharmaceutical Co. Ltd. 4,4-difluoro-1, 2, 3, 4-tetrahydro-5h-1-benzazepine derivatives or salts thereof
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
WO2004089380A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of fused 1,2,4-triazoles
WO2005080397A2 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
JP2006502162A (ja) * 2002-09-04 2006-01-19 ブリストル−マイヤーズ スクイブ カンパニー 成長ホルモン分泌促進剤として有用なヘテロ環状芳香族化合物
WO2006030805A1 (ja) * 2004-09-16 2006-03-23 Astellas Pharma Inc. トリアゾール誘導体またはその塩
JP2006522750A (ja) * 2003-04-11 2006-10-05 ノボ ノルディスク アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤および抗高血圧剤を使用する併用療法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501405B2 (en) * 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521666B1 (en) 1998-01-20 2003-02-18 Tanabe Seiyaku Co., Ltd. Inhibitors of α4 mediated cell adhesion
FR2796381A1 (fr) * 1999-07-12 2001-01-19 Hoechst Marion Roussel Inc Derives bicycliques de thioazepine ou de caprolactame, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
EP1445253A1 (en) 2001-11-16 2004-08-11 Yamanouchi Pharmaceutical Co. Ltd. 4,4-difluoro-1, 2, 3, 4-tetrahydro-5h-1-benzazepine derivatives or salts thereof
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
JP2006502162A (ja) * 2002-09-04 2006-01-19 ブリストル−マイヤーズ スクイブ カンパニー 成長ホルモン分泌促進剤として有用なヘテロ環状芳香族化合物
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
WO2004089380A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of fused 1,2,4-triazoles
JP2006522747A (ja) * 2003-04-11 2006-10-05 ノボ ノルディスク アクティーゼルスカブ 縮合1,2,4−トリアゾールの薬学的使用
JP2006522750A (ja) * 2003-04-11 2006-10-05 ノボ ノルディスク アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤および抗高血圧剤を使用する併用療法
WO2005080397A2 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
WO2006030805A1 (ja) * 2004-09-16 2006-03-23 Astellas Pharma Inc. トリアゾール誘導体またはその塩

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM. LETT., vol. 15, 2005, pages 1863 - 1865
ENDOCRINOLOGY, vol. 142, 2001, pages 1371
J. MED. CHEM., vol. 43, 2000, pages 4388 - 4397
J. ORG. CHEM., vol. 68, 2003, pages 2030 - 2033
JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, 2002, pages 3813
NATURE, vol. 414, 2001, pages 782
SCIENCE, vol. 294, 2001, pages 2166
T. W. GREENE ET AL.: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS, INC.
THE AMERICAN JOURNAL OF MEDICINE, vol. 108, 2000, pages 23
THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 89, 2004, pages 2601
THE JOURNAL OF CLINICAL INVESTIGATION, vol. 112, 2003, pages 83
THE LANCET, vol. 365, 2005, pages 1415
THEODORA W. GREENE; PETER G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, A WILEY-INTERSCIENCE PUBLICATION

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011007756A1 (ja) 2009-07-13 2011-01-20 武田薬品工業株式会社 複素環化合物及びその用途
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US8822699B2 (en) 2010-09-02 2014-09-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8901309B2 (en) 2010-09-02 2014-12-02 Takeda Pharmaceutical Company Limited Fused triazoles for the treatment or prophylaxis of mild cognitive impairment
WO2012144478A1 (ja) 2011-04-19 2012-10-26 第一三共株式会社 テトラヒドロチアゼピン誘導体
US8927536B2 (en) 2011-04-19 2015-01-06 Daiichi Sankyo Company, Limited Tetrahydrothiazepine derivative
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2746277A1 (en) 2012-12-19 2014-06-25 Basf Se Fungicidal imidazolyl and triazolyl compounds

Also Published As

Publication number Publication date
EP2119719A1 (en) 2009-11-18
JPWO2008078725A1 (ja) 2010-04-30
US20100004221A1 (en) 2010-01-07
TW200835502A (en) 2008-09-01

Similar Documents

Publication Publication Date Title
WO2008078725A1 (ja) チアゼピン誘導体
TW200606137A (en) Urea derivatives
EP1700856A4 (en) thiazole
EP1921077A4 (en) AGENT FOR THE TREATMENT AND / OR PREVENTION OF SLEEP DISORDERS
WO2008111441A1 (ja) 医薬組成物
WO2008105058A1 (ja) スルホンアミド化合物
WO2008093674A1 (ja) キナーゼ阻害活性を有する新規チアジアゾール誘導体
EP1541559A4 (en) 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE
TW200745032A (en) Novel heterobicyclic derivatives
WO2008120759A1 (ja) ウレア化合物およびその用途
WO2005037781A3 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
WO2008114819A1 (ja) 新規アデニン化合物
WO2008123469A1 (ja) 6員環アミド化合物およびその用途
TW200745034A (en) New compounds
TW200616994A (en) Novel thiophene derivatives
EP1845081A4 (en) amide
EP1726584A4 (en) 2-AMINOCHINAZOLINDERIVAT
WO2008140099A1 (ja) テトラゾイルオキシム誘導体および植物病害防除剤
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
WO2008057775A3 (en) Heterocyclic amide compounds useful as kinase inhibitors
EP1854789A4 (en) CHINAZOLINE DERIVATIVE WITH TYROSINE KINASE HEMMENDER EFFECT
TW200728298A (en) Thiophene compounds and thrombopoietin receptor activators
WO2008114812A1 (ja) Jak阻害剤
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
WO2008105526A1 (ja) マクロ環状化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07860009

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008551103

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007860009

Country of ref document: EP